Where does the data come from?

U.S. FDA National Drug Code (NDC) Directory via openFDA. Official record: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=43624-044

Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.: new drug for further processing listing

Q: How to monitor Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. and peer other records

FdaNdcDirectoryPulse lists new FdaNdcDirectoryPulse records from U.S. FDA National Drug Code (NDC) Directory via openFDA as they are published; a free weekly email digest and paid alerts follow records like this one.

Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.: new drug for further processing listing. Dated 44 days ago, it serves as a historical benchmark. Score 25/100. As of 2026-11-03, from U.S. FDA National Drug Code (NDC) Directory via openFDA.

Data as of 2026-11-03 · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA

Free preview: all 9 published fields of this record are shown below. Locked: 103 related FdaNdcDirectoryPulse records and the 5-column CSV export.

Field	Value
Generic name	Donanemab
NDC	43624-044
Labeler	BSP Pharmaceuticals S.p.A.
Product type	DRUG FOR FURTHER PROCESSING
Approval pathway	DRUG FOR FURTHER PROCESSING
Dosage form	INJECTION, SOLUTION
Active ingredients	DONANEMAB 17.5 mg/mL
Marketing start	2026-09-22
Package configurations	1
Peer records CSV (104 records)	🔒 Click to unlock →
CRM-ready export with official source URLs	🔒 Click to unlock →

View the official record

Markdown version

Watch Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.

Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.

Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.

Free first: a 10-record sample of records

See the real columns before you buy. One confirmation email, nothing else unless you opt in.

Unlock Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. + all 104 records (CSV)

Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Product · Labeler · Pathway · Form · Listed · official source URL

Source agency: U.S. FDA National Drug Code (NDC) Directory via openFDA
Record date: 2026-09-22
Data refreshed: 2026-11-03
Refunds on request within 14 days

Search all records free →

Top FdaNdcDirectoryPulse records (DRUG FOR FURTHER PROCESSING first): Lutetium (Lu 177) chloride (Lutetium (Lu 177) chloride) by C · Olibanum 1X (Olibanum 1X) by US Tinctures, LLC · ACYCLOVIR (ACYCLOVIR) by Isomedix Operations Inc · Water (Water) by Siegfried Hameln GmbH · Exosomes (Exosomes) by Regenerative Cell Research Institute · Browse all by state and category →

LIVE PUBLIC DATA Source: U.S. FDA National Drug Code (NDC) Directory via openFDA · Last refreshed: Tue, 03 Nov 2026 18:09:00 GMT

Is this your business? Add a "Listed on Zalwin" badge to your site

Paste this snippet into your website. It links to this public record; nothing is tracked on your site.

<a href="https://zalwin.com/report/fdandcdirectorypulse/donanemab-donanemab-by-bsp-pharmaceuticals-s-p-a-drug-for-further-processing--ndc-43624-044" rel="noopener"><img src="https://zalwin.com/badge/listed.svg" alt="Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. on Zalwin public records" width="150" height="28"></a>

Peer benchmark and outreach value: Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. and 104 DRUG FOR FURTHER PROCESSING peers

Your role Typical deal size (USD) Assumed reply-to-deal rate (%)

DRUG FOR FURTHER PROCESSING FdaNdcDirectoryPulse records like this one: 104
Timing: Low: older than 30 days
Estimated pipeline if you contact every DRUG FOR FURTHER PROCESSING peer: $20,800 (peers × rate × deal size; an estimate from your assumptions, not a forecast)

25 / 100 Launch Signal Score

Injectable: hospital and 503B relevance.

What is the FdaNdcDirectoryPulse record for Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.?

Donanemab by BSP Pharmaceuticals S.p.A.: new drug for further processing listing (DRUG FOR FURTHER PROCESSING) starting 2026-09-22.

How does Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. compare to other FdaNdcDirectoryPulse records?

It is 44 days old, still within a typical 45-day follow-up window. Its Launch Signal Score of 25/100 is modest; treat it as background rather than a priority.

Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. vs. top 3 peers

Organization	Location	Record date
Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.	DRUG FOR FURTHER PROCESSING	2026-09-22
Water (Water) by Siegfried Hameln GmbH	DRUG FOR FURTHER PROCESSING	2026-10-19
apitegromab (apitegromab) by Catalent Pharma Solutions, LLC	DRUG FOR FURTHER PROCESSING	2026-09-11
zilganersen (zilganersen) by Patheon Italia S.p.A.	DRUG FOR FURTHER PROCESSING	2026-09-04

Related records

FdaNdcDirectoryPulse: Other

How to monitor Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. and peer other records

Get new FdaNdcDirectoryPulse records like Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. by email (free, weekly)

We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.

Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.

See this week's digest

Get new listings in your categories

FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.

See plans

✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days

Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.